GLP's ⏱ Half-life: ~5-7 days

Pemvidutide

Pemvidutide (ALT-801)

Buy at SourcePeptides →
Half-Life
~5-7 days
Purity
Pharmaceutical grade (clinical trial material)
Mol. Weight
~4,100 Da
Form
Subcutaneous injection

What is Pemvidutide?

Pemvidutide (ALT-801) is being developed by Altimmune as a next-generation obesity therapeutic that specifically addresses the muscle loss problem inherent to GLP-1 monotherapy. By combining GLP-1 and glucagon receptor agonism, it aims to shift weight loss composition toward fat loss while preserving metabolically active lean tissue.

Dosage Information (Research Use)

Clinical trial doses: 1.2mg to 2.4mg subcutaneously once weekly. Not yet commercially available. Investigational compound.

Reconstitution & Handling

Clinical trial formulation.

Half-Life & Pharmacokinetics

~5-7 days

Reported Observations in Literature

Nausea, vomiting, diarrhea — similar GI profile to other GLP-1 RAs. Glucagon component may cause transient blood glucose elevations.

Key Research References

  • Altimmune press release. “MOMENTUM Phase 2 trial results.” 2023

How Pemvidutide Works

Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist. The glucagon component enhances energy expenditure and hepatic fat oxidation while the GLP-1 component provides appetite suppression. This dual action preserves lean mass during weight loss — a critical advantage over GLP-1-only approaches where 25-40% of weight lost can be lean tissue.

Research Applications

🔬 Obesity with focus on body composition
🔬 NASH/MASH (metabolic liver disease)
🔬 Liver fibrosis

Research Findings

Phase 2 MOMENTUM trial showed 15.6% weight loss at 48 weeks with significantly better lean mass preservation compared to semaglutide-class agents. Also showed 72.9% relative reduction in liver fat, positioning it as a potential MASH therapeutic.

Dosage & Administration

Clinical trial doses: 1.2mg to 2.4mg subcutaneously once weekly. Not yet commercially available. Investigational compound.

Safety & Side Effects

Nausea, vomiting, diarrhea — similar GI profile to other GLP-1 RAs. Glucagon component may cause transient blood glucose elevations.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight ~4,100 Da
Half-Life ~5-7 days
Purity Pharmaceutical grade (clinical trial material)
Form Subcutaneous injection
Storage Refrigerate 2-8°C.

Key Research References

  • Altimmune press release. "MOMENTUM Phase 2 trial results." 2023

Get Pemvidutide from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Exenatide
GLP's
First GLP-1 receptor agonist approved for diabetes, derived from Gila monster venom, available in twice-daily and once-weekly formulations.
View Profile → Buy at SP →
Liraglutide
GLP's
FDA-approved once-daily GLP-1 receptor agonist researched for glycemic regulation and weight management.
View Profile → Buy at SP →
Dulaglutide
GLP's
FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction, administered once weekly.
View Profile → Buy at SP →